Clinical Research Malaysia Bestows its Industry Recognition Award to Jeffrey Scott Yablon
Velocity Fund Partners Brings Healthcare and Life Sciences Experience and Connections To Complement InClinica’s Global Footprint
KUALA LUMPUR (March 22, 2016) – Jeffrey Scott Yablon has received an Industry Recognition Award from Clinical Research Malaysia for his outstanding efforts in promoting Malaysia as a preferred destination for Industry Sponsored Research (ISR).
“I’m honored to have been recognized by Clinical Research Malaysia with this award,” said Yablon. “Expanding business in Malaysia has opened up multiple opportunities for many. Malaysia offers unique benefits to the clinical research industry, and I’m truly honored to have been recognized for my efforts on behalf of the region.”
At CRM Industry Dialogue held on March 16, 2016, Yablon was recognized for his dual efforts in promoting clinical research in Malaysia and developing the clinical research ecosystem in the country.
Yablon, who heads the Asia/Pacific operations for InClinica – a global clinical CRO – has more than 20 years of experience in life science management. A long-time advocate of expanding business opportunities in Asia, Yablon has also been responsible for developing a clinical research training and certificate program for InClinica.
Yablon has a B.A. degree from Stockton University, an M.S. in Clinical Pharmacology from Stony Brook University and an EMBA in International Business Management from Fairleigh Dickinson University.
InClinica is a global clinical contract research organization founded in 2016 after the acquisition of an existing global CRO. With a senior management team that brings more than 100 combined years of experience, InClinica works across all phases of the clinical research process and has a particular strength in first in man and phase 2 studies. InClinica is headquartered in Philadelphia with other locations in the U.K., Israel, and Malaysia/Singapore.